PCSK9 and diabetes mellitus: Yet, while lowering plasma low‐density lipoprotein cholesterol (LDL‐C) is cardio‐protective, evidence over the past decade has recognized a role for common LDL‐C‐lowering variants, including loss‐of‐function variants in PCSK9 (Proprotein Convertase Subtilisin/ kexin Type 9) and HMGCR (3‐hydroxy‐3‐methylglutaryl‐CoA reductase), in higher risk for diabetes (Ference et al., 2016; Lotta et al., 2016; Schmidt et al., 2016; Swerdlow et al., 2015).